1. Scrip
  2. >>R&D

Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.

Scrip Five Must Know Things
audio roundup of selected content from Scrip's global team

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 12 April 2024, including: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca PLC looks to multiple cancer modalities; and an interview with Astellas Pharma, Inc.’s chief strategy officer.

This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "The Shifting Sands Of Biopharma R&D" - Scrip, 8 April, 2024.)

(Also see "Big Pharma Oncology Strategies Aim To Treat Cancer Earlier" - Scrip, 9 April, 2024.)

(Also see "Semaglutide Might Treat Heart Failure Directly" - Scrip, 8 April, 2024.)

(Also see "AstraZeneca Looks To Many Modalities In Cancer" - Scrip, 8 April, 2024.)

(Also see "Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs" - Scrip, 8 April, 2024.)

Citeline · Scrip's Five Must-Know Things - 15 April 2024

Open Media

More from R&D

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: Organon To Pull Plug On OG-6219 Program After Phase II Endometriosis Trial Failure

 
• By Sushmita Panda

Once hailed as a potential game changer, OG-6219 gets the axe after failing in a Phase II endometriosis-related pain trial.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 
• By Sushmita Panda

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

 
• By Lisa Takagi

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.

More from Scrip

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

 
• By Lisa Takagi

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 
• By Alaric DeArment

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.

Bluebird Builds Out Leadership Team Under Private Equity Ownership

 
• By Jessica Merrill

The gene therapy developer appointed a new president, chief medical officer and chief of staff following the closing of its acquisition by private equity firms Carlysle and SK Capital.